Epstein–Barr Virus‐Associated T/NK‐Cell Neoplasms

Epstein–Barr virus (EBV)‐associated T‐ and natural killer (NK)‐cell neoplasms encompass a heterogeneous spectrum, ranging from persistent lymphoproliferative disorders (e.g., severe mosquito bite allergy, systemic chronic active EBV disease) to highly aggressive malignancies (e.g., extranodal NK/T‐cell lymphoma [ENKTL], aggressive NK‐cell leukemia). Genomic and epigenetic studies have revealed shared host genetic alterations—most notably in JAK–STAT signaling, epigenetic regulators, TP53, and DDX3X—supporting a pathogenic and clinicobiological continuum across these disorders. Defective EBV further reshapes viral gene expression programs and contributes to oncogenesis. l‐asparaginase‐based chemoradiotherapy has improved outcomes in early‐stage ENKTL; however, effective treatments for advanced‐stage disease and other EBV‐associated T/NK‐cell neoplasms remain limited. Emerging molecular subclassifications and large‐scale prospective cohorts can help clarify disease heterogeneity and accelerate the development of precision therapeutic strategies.

• Publication year

  2026

• Venue

  Journal of Medical Virology

• Publication date

  2026-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jmv.70798PMID 41510998PMCID 12784803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

  2025cited by this paper
• The immune microenvironment of pathogen-associated cancers and current clinical therapeutics

  2025cited by this paper
• Defective but tumorigenic: the evolutionary and functional roles of mutated oncoviruses

  2025cited by this paper
• Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications

  2025influential reference
• Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell–type chronic active EBV infection

  2025cited by this paper
• Genetic and clinical distinction between aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma with bone marrow involvement

  2025cited by this paper
• Association of Epstein-Barr virus genomic alterations with human pathologies

  2025influential reference
• EBV+ nodal T/NK-cell lymphoma associated with clonal hematopoiesis and structural variations of the viral genome

  2024cited by this paper
• Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations

  2024cited by this paper
• Comprehensive genetic profiling reveals frequent alterations of driver genes on the X chromosome in extranodal NK/T-cell lymphoma.

  2024cited by this paper
• Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression

  2024cited by this paper
• Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation

  2024cited by this paper
• Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis.

  2023cited by this paper
• Updated guidelines for chronic active Epstein–Barr virus disease

  2023cited by this paper
• Epigenetic targets in B- and T-cell lymphomas: latest developments

  2023cited by this paper
• Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy

  2023cited by this paper
• Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma

  2023cited by this paper
• New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders

  2022cited by this paper
• Epstein-Barr virus: Biology and clinical disease.

  2022cited by this paper
• The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines

  2022cited by this paper
• EBV-associated NK and T-cell lymphoid neoplasms

  2022cited by this paper
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

  2022influential reference
• Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma

  2022cited by this paper
• The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.

  2022cited by this paper
• Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases

  2022cited by this paper
• EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1

  2022cited by this paper
• Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.

  2022cited by this paper
• Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies

  2022cited by this paper
• Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS

  2022cited by this paper
• EBV-associated diseases: Current therapeutics and emerging technologies

  2022cited by this paper
• Role of Epstein–Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma

  2021cited by this paper
• T-Cell Lymphoma Clonality by Copy Number Variation Analysis of T-Cell Receptor Genes

  2021cited by this paper
• RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells.

  2021cited by this paper
• Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV

  2021cited by this paper
• Estimating the global burden of Epstein–Barr virus-related cancers

  2021cited by this paper
• Epidemiology of Aggressive NK-Cell Leukemia in the United States: A SEER Population-Based Study

  2021cited by this paper
• Epigenetic Mechanisms in Leukemias and Lymphomas.

  2020cited by this paper
• Aggressive NK Cell Leukemia: Current State of the Art

  2020cited by this paper
• Epstein-Barr Virus Episome Physically Interacts with Active Regions of the Host Genome in Lymphoblastoid Cells

  2020cited by this paper
• The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis

  2020cited by this paper
• Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.

  2020cited by this paper
• Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.

  2020cited by this paper
• Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.

  2020cited by this paper
• Epigenetic specifications of host chromosome docking sites for latent Epstein-Barr virus

  2020cited by this paper
• Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders

  2019cited by this paper
• Defective Epstein–Barr virus in chronic active infection and haematological malignancy

  2019influential reference
• Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes

  2019cited by this paper
• Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America

  2019cited by this paper
• Integrated pan-cancer map of EBV-associated neoplasms reveals functional host-virus interactions.

  2019cited by this paper
• Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases

  2019influential reference
• Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

  2018cited by this paper
• The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis

  2018cited by this paper
• Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma

  2018cited by this paper
• Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases

  2018cited by this paper
• Chronic Active Epstein–Barr Virus Disease

  2017cited by this paper
• Epstein–Barr virus strains and variations: Geographic or disease‐specific variants?

  2017cited by this paper
• Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia

  2017cited by this paper
• Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes

  2017cited by this paper
• Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

  2016cited by this paper
• A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.

  2016cited by this paper
• Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

  2014cited by this paper
• EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

  2014cited by this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.

  2012cited by this paper
• Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

  2012cited by this paper
• Sequence variations of Epstein–Barr virus LMP1 gene in nasal NK/T-cell lymphoma

  2006cited by this paper
• Fulminant EBV+ T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome

  2000cited by this paper
• Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection.

  2000cited by this paper

• No citing papers are available for this paper.